keyword
MENU ▼
Read by QxMD icon Read
search

hepatitis B antiviral therapy

keyword
https://www.readbyqxmd.com/read/27920641/severe-de-novo-hepatitis-b-recovered-from-late-onset-liver-insufficiency-with-prolonged-ascites-and-hypoalbuminemia-due-to-hepatitis-b-virus-genotype-bj-with-precore-mutation
#1
Akira Sato, Toshiya Ishii, Fumiaki Sano, Takayuki Yamada, Hideaki Takahashi, Nobuyuki Matsumoto
De novo hepatitis B is associated with a high risk of hepatic failure often resulting in fatal fulminant hepatitis even when nucleotide analogues are administered. A 77-year-old female developed de novo hepatitis B after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) treatment for diffuse large B-cell lymphoma. Hepatitis B virus (HBV) isolated from the patient was of genotype Bj, with a precore mutation (G1896A) exhibiting an extremely high viral load at the onset of hepatitis...
September 2016: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/27917600/determination-of-hepatitis-b-phenotype-using-biochemical-and%C3%A2-serological-markers
#2
A M Di Bisceglie, M Lombardero, J Teckman, L Roberts, H L A Janssen, S H Belle, J H Hoofnagle
The aim of this study was to assess the validity of categorization of chronic hepatitis B viral infection into stages or phases based upon measures of disease activity and viral load, assuming these phenotypes will be useful for prognostication and determining the need for antiviral therapy. We assessed the phenotype of hepatitis B of 1,390 adult participants enrolled in the Hepatitis B Research Network Cohort Study, using a computer algorithm. Only 4% were immune tolerant, while 35% had chronic hepatitis B (18% e antigen positive and 17% e antigen negative) while 23% were inactive carriers...
December 5, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27895394/concise-review-interferon-free-treatment-of-hepatitis-c-virus-associated-cirrhosis-and-liver-graft-infection
#3
REVIEW
Nina Weiler, Stefan Zeuzem, Martin-Walter Welker
Chronic hepatitis C is a major reason for development of cirrhosis and hepatocellular carcinoma and a leading cause for liver transplantation. The development of direct-acting antiviral agents lead to (pegylated) interferon-alfa free antiviral therapy regimens with a remarkable increase in sustained virologic response (SVR) rates and opened therapeutic options for patients with advanced cirrhosis and liver graft recipients. This concise review gives an overview about most current prospective trials and cohort analyses for treatment of patients with liver cirrhosis and liver graft recipients...
November 7, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27892722/present-and-future-dna-vaccines-for-chronic-hepatitis-b-treatment
#4
Lucyna Cova
With at least 240 million hepatitis B virus (HBV) carriers worldwide, being at a high risk of cirrhosis and hepatocellular carcinoma (HCC), chronic hepatitis B remains a major public health issue. Because current antiviral treatments are only virostatic, there is an urgent need for the development of innovative anti-HBV strategies leading to the functional cure. In this context, DNA-based vaccines appear as a promising approach. Area covered: In this review, the authors summarize the pertinent features of DNA vaccines for chronic hepatitis B therapy...
November 28, 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27891715/baseline-hepatitis-b-core-antibody-predicts-treatment-response-in-chronic-hepatitis-b-patients-receiving-long-term-entecavir
#5
J-H Xu, L-W Song, N Li, S Wang, Z Zeng, C-W Si, J Li, Q Mao, D-Z Zhang, H Tang, J-F Sheng, X-Y Chen, Q Ning, G-F Shi, Q Xie, Q Yuan, Y-Y Yu, N-S Xia
Studies regarding the clinical significance of quantitative hepatitis B core antibody (anti-HBc) in patients with chronic hepatitis B receiving first-line nucleos(t)ide analogues is limited. The aim of this study was to determine the performance of anti-HBc as a predictor for hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive CHB patients treated with entecavir. This was a retrospective cohort study consisting of 139 Chinese patients enrolled in a multicenter clinical trial treated with entecavir or entecavir maleate for up to 240 weeks...
November 28, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27890170/hepatitis-b-reactivation-in-rheumatic-diseases-screening-and-prevention
#6
REVIEW
Christos Koutsianas, Konstantinos Thomas, Dimitrios Vassilopoulos
Hepatitis B virus (HBV) reactivation (HBVr) has been an increasingly recognized and appreciated risk of immunosuppressive therapies in rheumatic patients. Despite its potential for significant morbidity and mortality, HBVr is a fully preventable complication with appropriate pretreatment screening and close monitoring of susceptible patients. Better knowledge of the risk for HBVr with the different antirheumatic agents and the establishment of the new-generation oral antivirals in clinical practice has greatly improved the design of screening and therapeutic algorithms...
February 2017: Rheumatic Diseases Clinics of North America
https://www.readbyqxmd.com/read/27888529/long-term-progression-of-viral-load-and-serum-markers-of-fibrosis-among-treated-and-untreated-patients-with-chronic-hepatitis-b
#7
Jia Li, Stuart C Gordon, Loralee B Rupp, Talan Zhang, Sheri Trudeau, Scott D Holmberg, Anne C Moorman, Philip R Spradling, Eyasu H Teshale, Joseph A Boscarino, Yihe G Daida, Mark A Schmidt, Mei Lu
BACKGROUND AND AIMS: Antiviral therapy for patients with hepatitis B (HBV) infection is generally deferred for "immune inactive" patients, although longitudinal changes in viral load and liver fibrosis remain understudied in this population. Likewise, in treated patients, the temporal relationship between changes in viral load and liver fibrosis is not well-characterized. Using data from the Chronic Hepatitis Cohort Study, we investigated viral load and the Fibrosis-4 index (FIB4, a serum-based marker of liver fibrosis) trajectories in both untreated and treated HBV patients...
November 26, 2016: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27880997/efficacy-of-switching-from-adefovir-to-tenofovir-in-chronic-hepatitis-b-patients-who-exhibit-suboptimal-responses-to-adefovir-based-combination-rescue-therapy-due-to-resistance-to-nucleoside-analogues-satis-study
#8
Hye Won Lee, Jun Yong Park, Beom Kyung Kim, Moon Young Kim, Jung Il Lee, Young Suk Kim, Ki Tae Yoon, Kwang-Hyub Han, Sang Hoon Ahn
Background/Aims: It remains to be determined whether switching from adefovir (ADV) to tenofovir (TDF) provides better virological outcomes in patients exhibiting suboptimal responses to ADV plus nucleoside analogue (ADV+NA) therapy for NA-resistant chronic hepatitis B (CHB). Methods: In this prospective trial, patients who showed partial responses (defined as serum hepatitis B virus [HBV] DNA >60 IU/mL) to ADV+NA therapy for NA resistance were randomly allocated to receive TDF plus NA (TDF+NA group, n=16) or to continue their current therapy (ADV+NA group, n=16)...
November 25, 2016: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/27877054/adefovir-dipivoxil-is-less-expensive-than-lamivudine-and-associated-with-similar-prognosis-in-patients-with-hepatitis-b-virus-related-hepatocellular-carcinoma-after-radical-resection
#9
Jian-Hong Zhong, Yang Ke, Shao-Liang Zhu, Lin Wang, Cheng-Piao Luo, Wen-Feng Gong, Xue-Mei You, Liang Ma, Bang-De Xiang, Le-Qun Li
AIM: Lamivudine (LAM) and adefovir dipivoxil (ADV) are widely used in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), but few studies have directly compared their therapeutic efficacy and treatment cost. This study aims to compare LAM with ADV head-to-head in these patients. METHODS: We retrospectively analyzed 201 patients with HBV-related HCC who underwent radical resection and subsequently received LAM (n=155) or ADV (n=46). The two groups were compared in terms of HBV-DNA levels, liver function, antiviral resistance, recurrence-free, and overall survival, as well as antiviral medication costs...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27871021/stop-codons-in-the-hepatitis-b-surface-proteins-are-enriched-during-antiviral-therapy-and-are-associated-with-host-cell-apoptosis
#10
Danielle Colledge, Sally Soppe, Lilly Yuen, Lucy Selleck, Renae Walsh, Stephen Locarnini, Nadia Warner
Premature stop codons in the hepatitis B virus (HBV) surface protein can be associated with nucleos(t)ide analogue resistance due to overlap of the HBV surface and polymerase genes. The aim of this study was to determine the effect of the replication of three common surface stop codon variants on the hepatocyte. Cell lines were transfected with infectious HBV clones encoding surface stop codons rtM204I/sW196*, rtA181T/sW172*, rtV191I/sW182*, and a panel of substitutions in the surface proteins. HBsAg was measured by Western blotting...
November 18, 2016: Virology
https://www.readbyqxmd.com/read/27869323/comparative-treatment-effectiveness-of-direct-acting-antiviral-regimens-for-hepatitis-c-data-from-the-veterans-administration
#11
D S Fox, J J McGinnis, I Tonnu-Mihara, J S McCombs
BACKGROUND AND AIMS: Data addressing real world effectiveness of direct acting antiviral agents in hepatitis C infected patients are now emerging. This study compared the sustained virologic response rates achieved 12 weeks post-treatment in patients treated with three such agents by the Veterans Health Administration. METHODS: A retrospective cohort study was conducted using patients who terminated treatment by July 1, 2015. Data were retrieved from the Veterans Health Administration electronic medical records system...
November 21, 2016: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27868197/expression-of-a-hepatitis-b-virus-pre-s2-deletion-mutant-in-the-liver-results-in-hepatomegaly-and-hepatocellular-carcinoma-in-mice
#12
Yuan-Chi Teng, Jenq Chyuan Neo, Jaw-Ching Wu, Yi-Fan Chen, Cheng-Heng Kao, Ting-Fen Tsai
Hepatocellular carcinoma (HCC) is the most common form of liver cancer and has a poor prognosis and a low survival rate; its incidence is on the rise. Hepatitis B virus (HBV) infection is one of the main causes of HCC. A high prevalence of pre-S deletions of HBV surface antigen, which encompass T-cell and/or B-cell epitopes, is found in HBV carriers; antiviral therapy and viral immune escape may cause and select for these HBV mutants. In particular, the presence of pre-S2 deletion mutants is an important risk factor associated with cirrhosis and HCC...
November 21, 2016: Journal of Pathology
https://www.readbyqxmd.com/read/27864872/management-of-hepatitis-b-related-cirrhosis-in-the-era-of-effective-antiviral-therapy
#13
EDITORIAL
Vincent W S Wong
No abstract text is available yet for this article.
December 2016: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/27862721/efficacy-and-safety-of-tenofovir-disoproxil-fumarate-rescue-therapy-for-chronic-hepatitis-b-patients-who-failed-other-nucleos-t-ide-analogues
#14
Hiromitsu Kumada, Kazuhiko Koike, Kazuaki Suyama, Hiroshi Ito, Hiroshi Itoh, Wataru Sugiura
OBJECTIVE: Acquisition of nucleos(t)ide analogue (NA) inhibitors resistance is critical in successful chronic hepatitis B treatment. As the pattern of tenofovir disoproxil fumarate (TDF) resistance mutations differs from that of other antiviral drugs, we sought to clarify the salvaging potential of TDF in HBV patients who are poor responders or resistant to other NAs. MATERIALS AND METHOD: A prospective, multi-center, one-arm, open-label study was conducted from December 2011 to October 2014...
November 15, 2016: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/27861593/neutrophil-and-monocyte-function-in-patients-with-chronic-hepatitis-c-undergoing-antiviral-therapy-with-regimens-containing-protease-inhibitors-with-and-without-interferon
#15
Martina Gambato, Noelia Caro-Pérez, Patricia González, Nuria Cañete, Zoe Mariño, Sabela Lens, Martín Bonacci, Concepció Bartres, José-María Sánchez-Tapias, José A Carrión, Xavier Forns, Manel Juan, Sofía Pérez-Del-Pulgar, María-Carlota Londoño
Real-life data showed an increased incidence of bacterial infections in patients with advanced liver disease receiving a protease inhibitor (PI)-containing antiviral regimen against hepatitis C (HCV). However, the causes of this event are unknown. We hypothesized that PIs might impair innate immune responses through the inhibition of proteases participating in the anti-bacterial functions of neutrophils and monocytes. The aims of the study were to assess phagocytic and oxidative burst capacity in neutrophils and monocytes obtained from patients receiving a PI containing-antiviral regimen, and to determine cytokine secretion after neutrophil stimulation with flagellin...
2016: PloS One
https://www.readbyqxmd.com/read/27859587/gamma-glutamyl-transpeptidase-to-platelet-ratio-is-an-independent-predictor-of-hepatitis-b-virus-related-liver-cancer
#16
Yong Eun Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Sojung Han, Mi Young Jeon, Ja Yoon Heo, Kijun Song, Seung Up Kim
BACKGROUND AND AIMS: Gamma-glutamyl transpeptidase-to-platelet ratio (GPR) can evaluate the degree of liver fibrosis. We investigated whether GPR can predict the development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients. METHODS: We retrospectively evaluated 1,109 CHB patients that were enrolled between 2006 and 2012, and all patients had available data for the assessment of GPR at enrollment. Three risk groups were defined according to tertile stratification: GPR < 0...
November 16, 2016: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27855500/treatment-of-hepatitis-b-virus-an-update
#17
Haley Ward, Lydia Tang, Bhawna Poonia, Shyam Kottilil
Chronic hepatitis B virus infection is a global health concern as it affects over 240 million people worldwide and an estimated 686,000 people die annually as a result of complications of the disease. With the development of newer antiviral drugs, viral suppression of HBV is achievable, however elimination of HBV from infected individuals (functional cure) remains an issue. Due to persistence of HBV DNA (cccDNA) in infected cells, chronically infected patients who discontinue therapy prior to HBsAg loss or seroconversion are likely to relapse...
December 2016: Future Microbiology
https://www.readbyqxmd.com/read/27852658/indications-for-antiviral-therapy-for-chronic-hepatitis-b-in-pregnant-mothers
#18
Eric Raeyoon Yoo, Ryan Babu Perumpail, George Cholankeril, Aijaz Ahmed
The use of antiviral therapy for chronic hepatitis B virus (HBV) infection in the setting of pregnancy needs to be individualised based on limited data. We report a case of a 34-year-old Korean-American woman with a history of pregnancy with emergent caesarean section due to prolonged labour in the setting of HBV e-antigen (HBeAg) positive chronic HBV with a pretreatment baseline HBV DNA level of 110000 000 million copies per mL. Her first delivery was complicated by mother-to-child transmission (MTCT) of HBV infection to her daughter despite standard active and passive immunoprophylaxis...
November 15, 2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27849644/hepatitis-c-virus-infection-opportunities-for-an-earlier-detection-in-primary-care
#19
Francesco Lapi, Alice Capogrosso Sansone, Stefania Mantarro, Monica Simonetti, Marco Tuccori, Corrado Blandizzi, Alessandro Rossi, Giampaolo Corti, Alessandro Bartoloni, Alfonso Bellia, Leonardo Baiocchi, Iacopo Cricelli, Claudio Cricelli
BACKGROUND/AIM: In the era of direct-acting antiviral medications, which can cure the hepatitis C virus (HCV) infection, the actual epidemiology of this condition in the general population is still unclear. We therefore aimed to estimate the prevalence rate of HCV and assess the determinants for incident cases of HCV in primary care in Italy. METHODS: We identified outpatients aged at least 15 years registered in the Italian Health Search IMS Health Longitudinal Patient Database from 1 January 2002 to 30 June 2013...
November 15, 2016: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27847658/direct-acting-antivirals-in-patients-with-chronic-hepatitis-c-and-down-syndrome
#20
Eric R Yoo, Ryan B Perumpail, George Cholankeril, Aijaz Ahmed
Patients with Down syndrome who received blood transfusions, likely in conjunction with cardiothoracic surgery for congenital heart disease and prior to the implementation of blood-donor screening for hepatitis C virus infection, face a substantial risk of acquiring the infection. In the past, interferon-based therapy for chronic hepatitis C infection in patients with Down syndrome was noted to have lower efficacy and potentially higher risk of adverse effects. Recently, the treatment for chronic hepatitis C has been revolutionized with the introduction of interferon-free direct acting antivirals with favorable safety, tolerability, and efficacy profile...
2016: Case Reports in Infectious Diseases
keyword
keyword
32508
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"